0J8P.L

IDEXX Laboratories, Inc. [0J8P.L] Stock Forecast

Q: What is IDEXX Laboratories, Inc. stock symbol ?

IDEXX Laboratories, Inc. is a US stock, located in Westbrook of Me and trading under the symbol 0J8P.L

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

0J8P.L Stock Summary

Earnings have grown 8.72% per last year.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

0J8P.L has less than 1 year of cash runway

An RSI reading of 30 or below indicates an oversold or undervalued condition.

Top 10 Correlated ETFs

0J8P.L

Top 10 Correlated Stocks

0J8P.L

In the News

0J8P.L Financial details

Company Rating

Strong Buy

Market Cap

41.14B

Income

845.04M

Revenue

3.66B

Book val./share

17.87

Cash/share

5.46

Dividend

Dividend %

Employees

11K

Optionable

Shortable

Yes

Earnings

01 May 2024

P/E

56.39

Forward P/E

PEG

22.34

P/S

0.13

P/B

35.76

P/C

88.26

P/FCF

0.7

Quick Ratio

0.86

Current Ratio

1.43

Debt / Equity

0.65

LT Debt / Equity

0.42

EPS (TTM)

10.17

EPS next Y

EPS next Q

EPS this Y

25.25%

EPS next Y

EPS next 5Y

EPS last 5Y

15.4%

Revenue last 5Y

8.75%

Revenue Q/Q

-1.52%

EPS Q/Q

-8.24%

SMA20

-7.8%

SMA50

-6.27%

SMA100

8.58%

Inst Own

Inst Trans

ROA

27%

ROE

86%

ROC

0.51%

Gross Margin

60%

Oper. Margin

30%

Profit Margin

23%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

373.77-583.3

52W High

-17.34%

52W Low

+29.2%

RSI

29.76

Rel Volume

0.35

Avg Volume

1.08K

Volume

383

Perf Week

-6.37%

Perf Month

-13.57%

Perf Quarter

13.37%

Perf Half Y

11.7%

Beta

1.259

Volatility

9.61%, 22.05%

Prev Close

0.35%

Price

481.92

Change

-1.77%

0J8P.L Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	27.95	31.72	37.74	40.27	44.07
Net income per share	4.97	6.82	8.74	8.12	10.17
Operating cash flow per share	5.33	7.59	8.84	6.49	10.91
Free cash flow per share	3.53	6.33	7.43	4.59	9.3
Cash per share	1.05	4.5	1.7	1.35	5.46
Book value per share	2.06	7.41	8.1	7.28	17.87
Tangible book value per share	-1.4	3.95	2.72	1.79	13.47
Share holders equity per share	2.06	7.41	8.1	7.28	17.87
Interest debt per share	12.04	11.27	11.46	16.88	12.15
Market cap	57.78B	57.27B	56.48B	33.84B	46.05B
Enterprise value	58.76B	57.88B	57.37B	35.19B	46.67B
P/E ratio	135.1	98.43	75.83	49.82	54.5
Price to sales ratio	24.01	21.16	17.57	10.05	12.58
POCF ratio	125.85	88.36	75.02	62.36	50.8
PFCF ratio	190.12	106.01	89.18	88.18	59.59
P/B Ratio	325.59	90.6	81.85	55.58	31.02
PTB ratio	325.59	90.6	81.85	55.58	31.02
EV to sales	24.41	21.39	17.84	10.45	12.75
Enterprise value over EBITDA	93.1	73.07	54.48	35.61	38.65
EV to operating cash flow	127.98	89.32	76.19	64.87	51.48
EV to free cash flow	193.35	107.16	90.58	91.72	60.38
Earnings yield	0.01	0.01	0.01	0.02	0.02
Free cash flow yield	0.01	0.01	0.01	0.01	0.02
Debt to equity	5.65	1.47	1.37	2.25	0.65
Debt to assets	0.55	0.4	0.39	0.5	0.3
Net debt to EBITDA	1.55	0.78	0.84	1.37	0.51
Current ratio	0.88	1.74	1.18	0.84	1.51
Interest coverage	16.24	19.43	29.08	20.55	26.27
Income quality	1.07	1.11	1.01	0.8	1.07
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.1	0.11	0.1	0.1	0
Research and developement to revenue	0.06	0.05	0.05	0.08	0.05
Intangibles to total assets	0.16	0.13	0.19	0.17	0.11
Capex to operating cash flow	-0.34	-0.17	-0.16	-0.29	-0.15
Capex to revenue	-0.06	-0.04	-0.04	-0.05	-0.04
Capex to depreciation	-1.76	-1.12	-1.14	-1.42	-1.16
Stock based compensation to revenue	0.02	0.01	0.01	0.01	-0.09
Graham number	15.18	33.71	39.91	36.47	63.96
ROIC	0.36	0.37	0.45	0.33	0.34
Return on tangible assets	0.28	0.29	0.38	0.3	0.29
Graham Net	-14.36	-10.45	-13.49	-17.62	-8.84
Working capital	-90.23M	430.49M	136.66M	-191.57M	489.63M
Tangible asset value	-120.37M	336.91M	231.61M	149.27M	1.12B
Net current asset value	-1.02B	-648.52M	-846.97M	-1.09B	-334.22M
Invested capital	5.65	1.47	1.37	2.25	0.65
Average receivables	283.01M	341.11M	400.16M	458.24M	510.22M
Average payables	70.85M	73.37M	95.35M	113.18M	110.43M
Average inventory	184.16M	202.45M	239.45M	318.43M	374.05M
Days sales outstanding	46.63	50.54	48.31	53.21	52.79
Days payables outstanding	25.04	23.95	32.27	28.97	27.39
Days of inventory on hand	67.66	67.41	74.75	96.68	94.14
Receivables turnover	7.83	7.22	7.56	6.86	6.91
Payables turnover	14.58	15.24	11.31	12.6	13.33
Inventory turnover	5.39	5.41	4.88	3.78	3.88
ROE	2.41	0.92	1.08	1.12	0.57
Capex per share	-1.8	-1.26	-1.4	-1.9	-1.61

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	9.99	10.85	11.36	11.02	10.85
Net income per share	2.08	2.58	2.7	2.55	2.34
Operating cash flow per share	2.09	2.22	2.41	3.28	3.01
Free cash flow per share	1.49	1.74	2.08	2.87	2.62
Cash per share	1.36	1.34	1.6	3.99	5.46
Book value per share	7.34	10.13	13.17	15.61	17.87
Tangible book value per share	1.8	4.62	7.69	10.21	13.46
Share holders equity per share	7.34	10.13	13.17	15.61	17.87
Interest debt per share	16.68	14.88	12.84	12.61	11.74
Market cap	33.56B	41.3B	41.49B	36.56B	46.07B
Enterprise value	34.91B	42.51B	42.51B	37.37B	46.68B
P/E ratio	48.72	48.24	46.26	43.07	59.2
Price to sales ratio	40.5	45.88	43.97	39.93	51.09
POCF ratio	193.98	224.57	207.12	134.2	184.37
PFCF ratio	271.14	286.02	240.03	153.39	212
P/B Ratio	55.13	49.1	37.93	28.18	31.03
PTB ratio	55.13	49.1	37.93	28.18	31.03
EV to sales	42.14	47.22	45.05	40.82	51.77
Enterprise value over EBITDA	141.83	137.84	131.15	123.33	170.83
EV to operating cash flow	201.82	231.15	212.21	137.16	186.83
EV to free cash flow	282.1	294.39	245.93	156.78	214.82
Earnings yield	0.01	0.01	0.01	0.01	0
Free cash flow yield	0	0	0	0.01	0
Debt to equity	2.25	1.45	0.96	0.8	0.65
Debt to assets	0.5	0.44	0.37	0.34	0.3
Net debt to EBITDA	5.51	3.92	3.15	2.67	2.24
Current ratio	0.84	1.02	1.27	1.37	1.51
Interest coverage	15.26	21.33	25.48	30.63	32.62
Income quality	1	0.86	0.89	1.28	1.28
Dividend Yield	0	0	0	0	0
Payout ratio	0	0.04	0	0	0
Sales general and administrative to revenue	0.1	0.08	0.1	0.1	0
Research and developement to revenue	0.05	0.05	0.05	0.05	0.06
Intangibles to total assets	0.17	0.16	0.16	0.15	0.11
Capex to operating cash flow	-0.28	-0.21	-0.14	-0.13	-0.13
Capex to revenue	-0.06	-0.04	-0.03	-0.04	-0.04
Capex to depreciation	-1.71	-1.39	-0.99	-1.18	-1.09
Stock based compensation to revenue	0.02	0.02	0.02	0.02	-0.05
Graham number	18.52	24.25	28.27	29.95	30.68
ROIC	0.08	0.1	0.1	0.09	0.08
Return on tangible assets	0.08	0.09	0.09	0.08	0.07
Graham Net	-17.77	-15.31	-12.61	-10.46	-8.84
Working capital	-191.57M	26.44M	236.13M	354.67M	489.63M
Tangible asset value	149.27M	383.8M	638.72M	848.51M	1.12B
Net current asset value	-1.09B	-875.23M	-656.96M	-464.13M	-334.22M
Invested capital	2.25	1.45	0.96	0.8	0.65
Average receivables	471.9M	505.38M	526.07M	527.08M	525.7M
Average payables	110.18M	113.97M	112.69M	110.14M	111.63M
Average inventory	361.4M	379.42M	393.08M	394.56M	387.13M
Days sales outstanding	53.32	51.97	50.77	51.3	52.86
Days payables outstanding	28.12	29.63	26.14	27.48	26.4
Days of inventory on hand	93.85	98.42	95.94	96.14	90.73
Receivables turnover	1.69	1.73	1.77	1.75	1.7
Payables turnover	3.2	3.04	3.44	3.28	3.41
Inventory turnover	0.96	0.91	0.94	0.94	0.99
ROE	0.28	0.25	0.2	0.16	0.13
Capex per share	-0.59	-0.48	-0.33	-0.41	-0.39

0J8P.L Frequently Asked Questions

What is IDEXX Laboratories, Inc. stock symbol ?

IDEXX Laboratories, Inc. is a US stock , located in Westbrook of Me and trading under the symbol 0J8P.L

What is IDEXX Laboratories, Inc. stock quote today ?

IDEXX Laboratories, Inc. stock price is $481.92 today.

Is IDEXX Laboratories, Inc. stock public?

Yes, IDEXX Laboratories, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.08K
Market Capitalization 41.14B
Employee 11K
CEO Mr. Jonathan J. Mazelsky
Headquarters Westbrook,ME,US
IPO Date 2018-01-19
Website https://www.idexx.com

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.